Aurinia eye drug falls short in improving tolerability versus Restasis, but beats on efficacy

Allergan’s best-selling dry eye drug Restasis was developed after the immunosuppressant was originally shown to enhance tear production in dogs. Similarly, Canada’s Aurinia Pharma $AUPH found its experimental treatment was doing well in canine studies, prompting their evaluation of the drug — voclosporin opthalmic solution (VOS) — in humans.